Oncolytics Biotech and Orphan Drug Designations: Wash, Rinse, Repeat

REOLYSIN

Oncolytics Biotech (TSX:ONC, Nasdaq:ONCY) yesterday announced it had received orphan drug designation from FDA for their oncology drug, REOLYSIN, in the treatment of primary peritoneal cancer. This is the fourth time in less than a month that the company has announced an FDA orphan drug designation for REOLYSIN. Prior to yesterday’s orphan drug designation announcement […]

BioSyent is poised for a great 2015, says Cantor Fitzgerald Canada

Biosyent's leading brand is FeraMAX. It currently markets two formulations for the treatment of iron deficient anemia.

Investors should take advantage of recent softness in shares of BioSyent (TSXV:RX), says Cantor Fitzgerald Canada analyst Scott Curtis. Yesterday, BioSyent reported its fourth quarter and fiscal 2014 results. For the year, the company earned $3.15-million on revenue of $12.21-million, a topline that was up 57% year-over-year. “Two thousand fourteen marked our fifth consecutive year […]

Prometic Life Sciences should have strong clinical news flow in 2015

Prometic Life Sciences CEO Pierre Laurin

This past Friday, the tape was telling investors that something was up at Prometic Life Sciences (TSX:PLI). Prometic stock was surging on above average volume, even though there was no news from the company. Ultimately, IIROC stepped in and halted the stock late in the day due to pending news. Yesterday, investors learned that the […]

Oncolytics Biotech rises after FDA grants Reolysin orphan status for pancreatic cancer

REOLYSIN

Shares of Oncolytics Biotech (TSX:ONC, Nasdaq:ONCY) are up today after the company announced that the FDA had granted orphan drug designation lead product candidate, Reolysin, which is designed to treat various cancers. Today’s status relates to the treatment of pancreatic cancer. “This is the second indication for which we have received orphan drug designation in […]

Could Legal “Made in Canada” Marijuana Become a Global Export?

canadian club boardwalk empire

For decades, illegal marijuana has made its way down to the United States from Canada. “B.C. Bud” is a brand name that resonates with recreational marijuana users from Seattle to Sarasota. But could Canada’s first mover advantage in the business of marijuana translate into an industry that we could ultimately export to the United States? […]

Merus Labs rises on improved first quarter results

Sintrom

Shares of Merus Labs (TSX:MSL) are up today after the company reported better than expected first quarter results. In its Q1, reported after market yesterday, Merus lost $216,044 on revenue of $10.6-million, a topline that was up 70% over last year’s first quarter. “I am pleased with the substantial progress that our expanded Merus team […]

Canada’s long and odd anti-water fluoridation history

gordon sinclair

It’s been called one of the ten greatest public health achievements of the 20th century by United States Centers for Disease Control and Prevention. In 2012, 74.6% of the U.S. population had access to fluoridated water. The arguments for doing so seem clear: fluoridated water reduces the demineralization of tooth enamel and increases remineralization, thereby […]

Could Polio Return to the U.S. and Canada?

Dr. Jonas Salk at the Copenhagen airport in 1959.

In December, an outbreak of measles at Disneyland put a spotlight on the issue of vaccinations. According to the United States Centre for Disease Control (CDC) there were 644 cases of the measles from 27 states in 2014, the largest number of cases since it was thought to be eliminated in 2000. The culprit is […]

Shares of IMRIS off to fast start in 2015

Byron Capital Healthcare and Biotech analyst Douglas Loe says his aggressively postitive view that IMRIS's order flow can ramp up is based on the value proposition the company's products offer to hospital clients, which he believes are more than compelling.

Shares of IMRIS (TSX:IM, Nasdaq:IMRS) are up 18.2% today, a result shareholders must be growing used to in 2015. Since January 9th, when its shares closed at $0.72, IMRIS has nearly doubled, currently trading at $1.30. Those looking for a reason for the recent surge can probably point to the company’s press release of January […]

Miraculins President and CEO Christopher Moreau talks to Cantech Letter

Miraculins President and CEO Christopher Moreau

We are constantly and correctly reminded that early screening for a variety of diseases and conditions can drastically increase our chances of beating them. Yet for a myriad of problems, many of us end up simply avoiding the doctor’s office. We are too tired. We hate needles. And we’re probably fine, right? What if the […]